794522-90-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyrimidineacetonitrile is used as an intermediate in the synthesis of pharmaceuticals for its potential in developing anti-cancer and anti-inflammatory drugs. Its unique chemical structure allows for the creation of novel compounds with therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Pyrimidineacetonitrile is utilized as a building block in the production of various agrochemicals, contributing to the development of effective and environmentally friendly solutions for crop protection and pest control.
Used in Dye Production:
4-Pyrimidineacetonitrile is employed in the synthesis of dyes, where its chemical properties enable the creation of a wide range of colors and hues for various applications, including textiles, plastics, and printing inks.
Used in Organic Synthesis:
As a versatile building block in organic synthesis, 4-Pyrimidineacetonitrile is used for the development of new organic compounds with potential applications in various industries, such as material science, chemical research, and the creation of specialty chemicals.

Upstream product

• 3438-46-8 4-Methylpyrimidine 
• 36912-83-1 1-phenyl-2-(pyrimidin-4-yl)ethan-1-one 
• 7677-24-9 trimethylsilyl cyanide 
• 54198-81-1 4-pyrimidinylmethyl chloride 
• 179009-23-5 (E)-N,N-dimethyl-2-(pyrimidin-4-yl)ethen-1-amine 

Downstream Products

• 897645-25-9 5-amino-3-(2-chlorophenyl)-4-(4-pyrimidinyl)isoxazole 
• 897645-33-9 5-amino-3-(4-chlorophenyl)-4-(4-pyrimidinyl)isoxazole 
• 897645-82-8 5-amino-3-(2,4-difluorophenyl)-4-(4-pyrimidinyl)isoxazole 
• 897646-06-9 5-amino-3-(2,6-difluorophenyl)-4-(4-pyrimidinyl)isoxazole 
• 897646-36-5 5-amino-3-(2,6-dichlorophenyl)-4-(4-pyrimidinyl)isoxazole 
• 897647-04-0 5-amino-3-(3-methylphenyl)-4-(4-pyrimidinyl)isoxazole 
• 897647-50-6 5-amino-3-(4-fluoro-3-methyl)-4-(4-pyrimidinyl)isoxazole 
• 897644-70-1 5-amino-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole 

Relevant academic research and scientific papers

Modulating Photostability and Mitochondria Selectivity in Far-Red/NIR Emitting Coumarin Fluorophores through Replacement of Pyridinium by Pyrimidinium

Mitochondrial dysfunction has been associated with several human pathological conditions, including cancer, aging, and neurodegenerative diseases. Thus, the availability of selective fluorescent probes for mitochondria could play an important role in the future for monitoring cellular functions and disease progression. In this work, we have studied how the photophysical properties and subcellular accumulation of nonconventional coumarin-based COUPY fluorophores can be fine-tuned through replacement of the para-pyridinium moiety with several heterocycles. Among them, ortho,para-pyrimidinium substitution provided novel fluorophores with suitable photophysical properties for bioimaging applications, including emission in the far-red to NIR region, large Stokes' shifts, and high photostability. Furthermore, the compounds exhibited excellent cell membrane permeability in living cells and a higher selectivity for mitochondria compared with the parent COUPY fluorophores. Overall, these results provided useful insights into the development of novel mitochondria-targeted fluorescent probes based on small organic molecules, since higher selectivity for this organelle can be achieved through the replacement of conventional N-alkylated pyridinium moieties by the corresponding N-alkylated-ortho,para-pyrimidinium counterparts.

An efficient and practical method for the synthesis of the 5-acylamino-4-(4-pyrimidinyl)isoxazole derivative AKP-001, a potent P38 map kinase inhibitor

5-Acylamino-4-(4-pyrimidinyl)isoxazole derivative AKP-001 is a p38 mitogen-activated protein kinase inhibitor previously developed in our laboratory as an anti-inflammatory agent. Herein, we report our studies leading to the development of an improved syn

FTO INHIBITORS

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4- fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept

Inhibitors of p38 mitogen-activated protein (MAP) kinase, which are closely involved in the production of inflammatory cytokines, are considered promising curative drugs for chronic inflammatory disorders. However, there is also a growing concern regarding its systemic side effects. To reduce the occurrence of side effects, we have identified a novel p38 MAP kinase inhibitor that shows properties of an antedrug, which imparts its effect solely on the inflammatory site and is metabolically inactivated right after. We have designed isoxazole derivatives through the addition of a fresh interacting fourth site to the structure of the prototypical p38 MAP kinase inhibitor that harbors three point interactive sites. The derivative 26d (AKP-001) shows excellent p38 MAP kinase inhibitory activity and a high selectivity for various kinases. Its rapid metabolism has been confirmed in rats. Moreover, 26d has been shown to be effective in animal models of inflammatory bowel disease.

TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE

The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.